Price (delayed)
$9.2
Market cap
$495.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.27
Enterprise value
$34.66M
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating
There are no recent dividends present for PRTA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.